key: cord-0705934-dfkoso7t
authors: Vitiello, Antonio; Ferrara, Francesco
title: Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients
date: 2021-09-16
journal: Current research in pharmacology and drug discovery
DOI: 10.1016/j.crphar.2021.100056
sha: 80a486cb38b0f0960ee2a94fbeff5fd642108020
doc_id: 705934
cord_uid: dfkoso7t

The COVID-19 global pandemic has caused about 4,30 Mln deaths. Recently the first vaccines have been licensed, representing the most powerful weapon available to stop the pandemic. The COVID-19 viral infection in the most severe cases can cause severe lung lesions with the presence of fibrotic tissue. Even among cured individuals, the presence of pulmonary fibrotic tissue may be the major cause of long-term complications of COVID-19 requiring antifibrotic therapeutic treatment even in the post-COVID-19 infection phase to accelerate the healing process and fully recover lung function. This article reviews the fibrogenic mechanism of SARS-CoV-2-induced viral damage and the antifibrotic treatments indicated to treat sequelae post COVID-19 infection.

In November 2019, a sudden surge of patients admitted to hospitals in Wuhan, China, due to severe pneumonia of viral origin was identified 1 . The rapid exponential increase in the number of cases suggested the possibility of human-to-human transmission. 2-3 On January 7, 2020, Chinese scientists isolated a new coronavirus from samples taken from the airways of hospitalized patients 4 . This viral agent has been named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 5 . The World Health Organization (WHO) declared this new viral disease a global public health emergency on January 30, 2020, and subsequently declared SARS-CoV-2 global pandemic status (COVID-19) on March 11, 2020 6 . To date, data record 400 Mln infected and 4,30 Mln deaths worldwide. SARS-CoV-2, following spike (S) protein binding, penetrates host cells via attachment to the angiotensinconverting enzyme-2 (ACE2) receptor. After endocytosis, the viral RNA genome is released into the host cell. ACE-2 is expressed in numerous tissues; therefore, it is believed that SARS-CoV-2 can penetrate and infect several target organs, from the lungs to the heart, liver, and testes 7 . Transmission occurs from human to human 8 . The onset of the first symptoms of the disease has been reported within a period of 14 days after exposure to the virus. Current epidemiologic evidence indicates that the highest morbidity affects individuals of advanced age and with preexisting comorbidities. Because of the urgency and rapidity of action, treatments used to treat infection have been experimental and mostly indicated to avoid serious complications [9] [10] . Recently, the first vaccines have been licensed, using mRNA, viral vector and protein subunit methods 11-12-13 . Pulmonary fibrosis caused by SARS-CoV-2 is an important clinical consequence of COVID-19 infection. Pulmonary fibrosis is also a common sequela of COVID-19 patients in recovery, compromising quality of life in some cases. Evidence has shown that cytokines involved in the development of pulmonary fibrosis are increased in severe COVID-19 patients, this suggests that pulmonary fibrosis plays an important role in the development of severe disease in COVID-19 patients.

Evidence shows that COVID-19 viral infection can exacerbate preexisting respiratory diseases, particularly pulmonary fibrose (PF). A direct pathophysiologic relationship between COVID-19 viral infection and stable or progressive fibrosis is not entirely clear, although some data suggest a potential fibrosis caused by the infection, even after recovery from the virus. [14] [15] Fibrosis may take a course as a stable disease in response to infection, or progressive also characterized by periods of rapid exacerbation. COVID-19 can cause lung lesions with the presence of fibrotic tissue even after virus eradication. The fibrotic lung condition may be associated with a thickening of the alveolar walls obstructing the normal physiology of gas exchange and decreasing lung function. COVID-19 patients with symptomatic and then cured disease are at increased risk of developing fibrotic disease and longterm damage. 16 Therefore, it is critical to know the pathophysiological pathways activated by COVID-19 to identify the most effective targeted treatments to accelerate resolution and the healing process. 17-18-19 Although to date, the genetic predisposition that makes some individuals more susceptible to severe COVID-19 infection than others is still unclear, in view of the very high number of infected individuals, the best therapeutic strategies to treat the current infection, but also the postinfection sequelae, must be identified.

Bilateral interstitial pneumonia caused by COVID-19 infection is associated with the presence of fibrotic tissue caused by excess collagen (fibrosis) in the pulmonary interstitium with hyperinflammation present. SARS-CoV-2 infection in its most severe stages is characterized by a generalized hyperinflammatory state, induced by a cytokine storm, causing pulmonary and multiorgan injury. This massive and sudden release of proinflammatory cytokines, such as tumor necrosis factor alpha TNF-α and interleukin-1-beta (IL-1β) causes acute inflammatory fibrotic lung disease. At this stage of infection COVID-19, activated macrophages contribute to the induction of neutrophil recruitment 20 contributing to the generation of reactive oxygen species (ROS). This response is useful in eliminating the virus, but in excess and abnormal can result in tissue damage [21] [22] . In addition, activation of fibroblasts deposits collagen to repair tissue damage. However, even when the fibroblast response is unregulated it can cause increased thickness, stiffness, and alteration of the normal structure of the lung pathways. Some evidence shows that the formation of fibrotic lung tissue in severe COVID-19 patient is also caused by an excess of chemokines 23 . Moreover, activated macrophages and fibroblasts produce large amounts of TGFb which produces increased extracellular matrix, collagen deposition, and subsequent increase in tissue stiffness. From a molecular point of view, other mechanisms are responsible for the formation of pulmonary fibrotic tissue in COVID-19 patients. In particular, SARS-CoV-2 penetrates cells through the ACE-2 receptor, this is expressed in alveolar pneumocytes. ACE2 is a regulator of the renin-angiotensin system (RAS). The RAS system consists of a classical ACE-dependent pathway and a nonclassical ACE-2-dependent pathway. In severe stages of COVID-19 infection, a dysregulated RAS system may contribute to excessive production of Ang II, synthesized by the classical ACE-dependent pathway, with profibrotic, and inflammatory effects. In contrast, the non-classical ACE-2 pathway appears to be reduced, with decreased production of antifibrotic and anti-inflammatory mediators such as Ang (1-7) and Ang (1-9). 24-25-26 Increased Ang II causes activation of tumor necrosis factor-a (TNFa), interleukin (IL)-6, TGFb, and increased recruitment of neutrophils and macrophages, which are critical factors in a fibrotic response. However, the increase in these described proinflammatory factors, increased Ang II, and activation of downstream mediated pathways should be carefully considered and evaluated even after recovery from COVID-19. (Figure 1 ) In the most severe phases of the infection, a generalized inflammatory state induced by the cytokinetic cascade may appear, and in parallel a state of systemic hypercoagulability characterized by the tendency of venous, arterial and microvascular thrombosis. In these subjects high levels of D-dimer and fibrinogen alterations, a slight prolongation of the prothrombin time are frequently detected. The consequent damage to the alveolar epithelium causes the release of pro-inflammatory cytokines and excessive deposition of collagen, with the formation of fibrotic tissue (Figure 1 ). Several studies also show ARDS in the lungs and microangiopathic, hemorrhagic and thrombotic phenomena with widespread alveolar damage.

The direct viral damage at the endothelial level is determinant in the hyperactivation of coagulation. 27 The damage to the endothelium can cause circulatory dysfunction, vasoconstriction, with consequent ischemia and inflammation of the microcirculation. In addition, the inflammatory state itself is an important trigger for the coagulation cascade. Finally, the platelet component of coagulation is also activated during COVID-19 infection. In autopsy lung tissue, the abundant presence of megakaryocytes suggests a correlation with the finding of widespread small platelet-rich thrombi. Platelets, in fact, can promote an immune-mediated response causing tissue infiltration and, in critical phases, thrombocytopenia. The latter is essentially always present in severe pictures of COVID-19 J o u r n a l P r e -p r o o f disease. [28] [29] This shows that the mechanism of pulmonary fibrosis in COVID-19 is different from that in IPF and other fibrotic lung diseases.

Some evidence shows that certain risk factors such as age, severity of COVID-19 disease, use of mechanical ventilation, and smoking may contribute more to the development of pulmonary fibrosis. 30 Elderly patients are more likely to develop severe symptoms from COVID-19. Laboratory evidence indicates that elevated lactate dehydrogenase (LDH) levels correlate with increased disease severity and risk of developing pulmonary fibrosis. LDH is an indicator of lung tissue destruction and correlates with mortality risk. Severe COVID-19 patients may require intensive care. Mechanical ventilation may be an additional risk factor for ventilator-induced lung injury (VILI). Ventilatorinduced lung injury is an acute lung injury resulting from or exacerbated by mechanical ventilation that leads to the release of proinflammatory mediators, presence of pulmonary fibrosis, and increased mortality. In a follow-up study of 27 patients undergoing mechanical ventilation for ARDS, 110-267 days after extubation, 23 patients (85%) had pulmonary fibrosis with a significant relationship to duration of ventilation. 30

To date, there is open debate whether individuals recovered from COVID-19 infection with sequelae, may present with irreversible airway damage with the presence of progressive post-infection fibrose or reversible damage that with appropriate therapy may recur. Other outbreaks caused by similar viruses such as MERS or SARS-CoV suggest that post-infection pulmonary fibrose could be a problem. Epidemiologic evidence indicates that 33% of patients recovered from MERS had pulmonary fibrose in the postinfection setting 27 . Studies of SARS-CoV have indicated that 27.8% to 62% of patients infected with SARS-CoV showed decreased lung function and increased fibrose 31-32-33 . In a 15-year follow-up from the 2003 SARS outbreak, 9% of study participants experienced fibrose after infection, and this percentage decreased within 1 year and remained stable until a 15-year followup in 2018 34 . The study found that most patients recovered from interstitial damage and functional decline within 2 years of rehabilitation . What proportion of COVID-19 patients developed pulmonary fibrose remains speculative and should not be assumed without an appropriate prospective study. A study shows 35 Lung lesions in 64.7% of discharged patients were completely absorbed after 4 weeks of follow-up. This indicated that lung damage caused by COVID-19 might be reversible for common COVID-19 patients. It also suggested that the prognosis of non-severe patients is favorable, and clinical intervention should be conducted in time to prevent common COVID-19 patients from worsening into severe patients. Many studies have shown that the most common abnormality of lung function in survivors discharged with COVID-19 is impaired diffusion capacity, followed by restrictive ventilatory defects, both of which are associated with disease severity [36] [37] . The cytokine storm that occurs in the most severe stages of infection can lead to the initiation and promotion of pulmonary fibrosis. Dysregulated release of matrix metalloproteinases, VEGF, and cytokines cause epithelial and endothelial damage in the airways. In particular, some individuals develop progressive pulmonary fibrosis induced by the accumulation of fibroblasts excessive collagen deposition.

Pulmonary fibrosis has been identified as the major cause of lung dysfunction in patients who survived severe SARS-CoV-2 infection. Thus, there is an urgent need to identify biomarkers for early detection of post COVID-19 infection patients at risk of developing persistent lung fibrosis with subsequent risk of mortality. Probably the data and knowledge acquired on the pathophysiological mechanisms of lung fibrosis can also be used to identify post-COVID-19 patients at higher risk of persistent fibrotic lung damage by directing the best choices of drug treatment. A number of noninvasive, serologic biomarkers may be important to rapidly detect tissue remodeling and fibrosis, and subsequent decline in lung function 38 . In the absence of pathology, the extracellular matrix (ECM) in the airways separates capillaries from the alveolar space and allows gas diffusion. In the presence of fibrotic tissue, the ECM expands limiting this function. The fibrotic ECM is composed of fibronectin and collagen types I, III, and VI. 39 An important tool to prevent COVID-19 development of pulmonary fibrotic tissue is to understand the effects of COVID-19 infection on pulmonary ECM romodeling using appropriate markers. Neoepitope technology is useful to detect the generation of newly formed epitopes of collagens and other ECM proteins that form during fibrosis [40] [41] . These neoepitope markers may be associated with the progression of Pulmonary Fibrosis in COVID-19 patients. The value of D-Dimer may also be considered, in severe COVID-19 patients there is dysregulation of coagulation. A study stratified a sample of 239 patients with pulmonary fibrosis during hospitalization according to their degree of pulmonary fibrosis at discharge, biological marher and their clinical characteristics were analyzed. Patients with and without pulmonary fibrosis had statistically significant differences in age, IL-6 levels, % lymphocytes, aspartate transaminase (AST), albumin, CRP/albumin ratio, and platelet/lymphocyte ratio, suggesting that these abnormal clinical indicators may be related to pulmonary fibrosis. 42 Antifibrotic treatment post COVID-19 infection needs to be undertaken in a timely manner in order to accelerate the healing process and resume full lung function

The management of drug treatments of the severe COVID-19 patient is complex. The benefit/risk ratio of the pharmacologic agents used should be carefully monitored 43-44-45 . Appropriate use of medications may reduce the risk of severe COVID-19 complications and postinfection sequelae. To date, no fully proven epidemiological evidence is available for the treatment of post COVID 19 infection pulmonary fibrose, in this direction various treatment strategies are being evaluated. It has been proposed that the appropriate use of antivirals, antifibrotics 46-47-48 , and anti-inflammatory agents reduces the risk of developing pulmonary fibrose. However, among the antivirals and antiinflammatory drugs, it is yet to be fully elucidated which of them has the greatest efficacy in preventing lung remodeling and fibrosis. Synthetic glucocorticoid drugs and interleukin inhibitors (eg, Tocilizumab, Sarilumab) used in severe phases of COVID-19 infection, by reducing the hyperactive and generalized inflammatory state may indirectly also prevent the formation of fibrotic lung tissue 49 . Same rationale for use also applies to colchicine. The use of large doses of glucocorticoid drugs could worsen hyperglycemia and contribute to proximal myopathy, which in turn would delay patients' mobility and rehabilitation. 50 Pirfenidone and nintedanib, are drugs used for the treatment of Idiopathic Pulmonary Fibrosis (IPF). 51-52-53 They are drugs with pleiotropic, antifibrotic, antioxidant, and anti-inflammatory effects that can be used in the acute phase of COVID-19 infection and in the pharmacological treatment of the post COVID-19 pulmonary fibrotic state, for a better and faster healing process. 54-55-56 In particular, pirfenidone possesses anti-inflammatory activity by suppressing the activation of the NLRP3 inflammasome. Probably the use of pirfenidone immediately at the onset of acute respiratory syndrome from SARS-CoV-2 may prevent more consequences such as pulmonary fibrosis. In addition, it should be considered that both of these antifibrotic drugs require at least 1-3 months to demonstrate a clinical efficacy effect. This has been demonstrated in the INBUILD, and INPULSIS studies, [57] [58] Thus, the time of initiation of antifibrotic treatment is critical; adding them at a late stage in patients requiring ventilatory support may not be optimal. Patients with the most severe ARDS are best suited for antifibrotic therapy. Such patients will generally require prolonged ventilation with high oxygen requirements, and perhaps antifibrotics along with steroids (which have already become the standard of care) could play a role in preventing or delaying the fibrosis that many of these patients will develop. Another interesting line of research to prevent and reduce the pulmonary fibrotic state in post COVID-19 infection patients is to act on the RAS system. As described above, decreased expression of ACE-2 and increased synthesis of Ang II may result in inflammatory and profibrotic effects. Several agents under consideration could include soluble recombinant human ACE2 (hrsACE2) with a dual mechanism of action anti COVID-19, 2 binds the viral spike protein neutralizing SARS-CoV-2, and minimizes damage to multiple organs, including the lungs, kidneys, and heart, by reducing Ang II concentrations and increasing conversion to Ang (1-7) with anti-inflammatory antioxidant and antifibrotic effects. Another novel approach in this direction is the use of the ACE2-like enzyme 59-60-61 . An example of such experimental agents is B38-CAP. B38-CAP shares structural similarity with ACE2. In vitro evidence shows that the recombinant B38-CAP protein catalyzes the conversion of angiotensin II to Ang 1-7. Finally, another approach in this direction is the administration of Ang-derived plasma (1-7) in COVID-19-positive patients. Several clinical trials are underway to confirm these interesting hypotheses62 62-63-64 . Thus, the identification of biomarkers from the onset of COVID-19 infection is urgently needed to identify patients who are likely to progress to pulmonary fibrose. The use of antiinflammatory and antibrotic therapy should be tailored with careful monitoring of the benefit/risk profile of the agents used. (Figure 2 ) One of the most promising therapeutic approaches in the treatment of post COVID-19 pommel fibrosis is stem cell therapy(MSC) 65 . Infection with COVID-19 triggers an exaggerated exaggerated immune reaction in the body by producing large amounts of various inflammatory factors including several cytokines, chemokines, and immunoreactive cells. MSC therapy could prevent the triggering of the cytokine storm by the activated immune system, and the reparative properties of stem cells could promote endogenous repair. In addition, novel antifibrotic therapies may include molecules that block integrins and galectins in the TGF-beta pathway, and also act to inhibit viral infection. 66 Another treatment in Covid-19 are PDE4 inhibitors (PDE4i). These have recently been suggested as promising molecules to beat the severe inflammation in Covid-19 by acting to block the infiltration of neutrophils, monocytes, and lymphocytes and to reduce the production of inflammatory cytokines and chemokines from these cells and the lung epithelium. 67 Finally, those who have had significant respiratory disease may benefit from pulmonary rehabilitation.

Severe acute infection occurring in the airways of severe COVID-19 patients is a disease that can lead to pulmonary fibrosis and permanent disability. There are few options available for its treatment. The most important factor in limiting pulmonary fibrosis is early, timely antiviral treatment and elimination of the causative viral agent, and antiinflammatory treatment with glucocorticoids directed at reducing the inflammatory state that generates pulmonary fibrosis. In addition, antifibrotic therapies consisting of pirfenidone, nintedanib, and promising MSC therapy may be considered.In addition, another important line of research is the

A novel coronavirus outbreak of global health concern

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China

An Update on Molecular Diagnostics for COVID-19

Three Emerging Coronaviruses in Two Decades

A pneumonia outbreak associated with a new coronavirus of probable bat origin

SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan

Cytokine storm and colchicine potential role in fighting SARS-CoV-2 pneumonia

Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19

Colchicine and SARS-CoV-2: Management of the hyperinflammatory state

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Viral infection and aging as cofactors for the development of pulmonary fibrosis

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

Therapeutic Strategies for SARS-CoV-2 acting on ACE-2

Remdesivir versus ritonavir/lopinavir in COVID-19 patients

Alveolar macrophage -derived exosomes modulate severity and outcome of acute lung injury

Neutrophil-Airway Epithelial Interactions Result in Increased Epithelial Damage and Viral Clearance during Respiratory Syncytial Virus Infection

β2-integrin LFA1 mediates airway damage following neutrophil transepithelial migration during respiratory syncytial virus infection

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?

Drugs acting on the renin-angiotensin system and SARS-CoV-2. Drug Discov Today

Potential pharmacological approach in the regulation of ACE-2 and DPP-IV in diabetic COVID-19 patient

Endothelial cell infection and endotheliitis in COVID-19

Coronin 1A, a novel player in integrin biology, controls neutrophil trafficking in innate immunity

Platelet count decline: an early prognostic marker in critically ill patients with prolonged ICU stays

Pulmonary fibrosis in COVID-19 survivors: Predictive factors and risk reduction strategies

Follow-up chest radiographic findings in patients with MERS-CoV after recovery

SARS: prognosis, outcome and sequelae

Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors

The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors

Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year followup from a prospective cohort study

Chest Computed Tomography and Clinical Follow-Up of Discharged Patients with COVID-19 in Wenzhou City

Abnormal carbon monoxide diffusion capacity in COVID-19 patients at time of hospital discharge

Abnormal pulmonary function in COVID-19 patients at time of hospital discharge

Can biomarkers of extracellular matrix remodelling and wound healing be used to identify high risk patients infected with SARS-CoV-2?: lessons learned from pulmonary fibrosis

The good and the bad collagens of fibrosis-their role in signaling and organ function

High levels of biomarkers of collagen remodeling are associated with increased mortality in COPD-results from the ECLIPSE study

Collagen biology and non-invasive biomarkers of liver fibrosis

Clinical characteristics and factors associated with mortality in idiopathic pulmonary fibrosis: An experience from a tertiary care center in Pakistan

Antirheumatic in SARS-CoV-2: benefit or risk?

Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times?

The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced

Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?

Remdesivir and COVID-19

Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. Med Hypotheses

Efficacy of synthetic glucocorticoids in COVID-19 endothelites

Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade

The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?

COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view

Scientific Hypothesis for Treatment of COVID-19's Lung Lesions by Adjusting ACE/ACE2 Imbalance

Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients

Anti-fibrotic therapy for the treatment of pulmonary sequelae in patients healed by COVID-19

Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON

The advantages of drug treatment with statins in patients with SARS-CoV-2 infection

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects

A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome

B38-CAP is a bacteria-derived ACE2-like enzyme that suppresses hypertension and cardiac dysfunction

Stem cell therapy for COVID-19, ARDS and pulmonary fibrosis

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

Rationale for evaluating PDE4 inhibition for mitigating against severe inflammation in COVID-19 pneumonia and beyond

The authors have nothing to say about ethical standards, ethical approval and funding. This manuscript is not a clinical trial and does not violate ethical rules. No funding has been received for its preparation.

I, The undersigned, Francesco Ferrara and any other author, declare that: The manuscript was written entirely by the authors;  All authors made an equal contribution in the development of the paper;  We have no conflict of interest;  We have not received funding/source;  There are no sensitive data and no patients were recruited for this study;  The document does not conflict with ethical legislation.  The authors accept the full TRANSFER OF COPYRIGHT to the journal.

Not applicable

Not applicable

The authors consent to the publication of the manuscript All authors read and approved the manuscript and all data were generated in-house and that no paper mill was used

None of the Authors have conflicts of interest to disclose.

Full availability of data and materials